Latest Revenue Growth News

Netwealth Group Limited has reported a stellar FY25 with record funds under administration net flows of $15.8 billion and a 31% rise in EBITDA, underpinned by strong adviser growth and strategic technology investments.

EQT Holdings Limited reported record funds under management and a solid financial performance for FY25, successfully completing its three-year strategic integration program. The company’s margin recovery and dividend growth signal a confident outlook amid ongoing regulatory challenges.

Equity Trustees reports record funds under management of $254 billion and a 60% jump in statutory net profit, completing a transformative three-year strategic agenda.

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

Qube Holdings Limited reported robust FY25 underlying revenue growth of 27%, driven by strong performances in its Logistics & Infrastructure and Ports & Bulk divisions, while declaring a 71% increase in full-year dividends. Despite challenges including industrial action and weather disruptions, Qube expects continued earnings growth in FY26 supported by strategic acquisitions and operational resilience.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Megaport Limited reported a 16% revenue increase to $227.1 million in FY25, alongside a 20% rise in Annual Recurring Revenue, while posting a slight net loss of $0.3 million. The company expanded its global footprint and launched innovative new services, setting the stage for continued growth in FY26.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.